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Abstract
Background: Conditional survival (CS) measures the probability that patients will survive an additional number of
years given that they have already survived for a certain period of time.
Methods: In total, 2935 gastric cancer patients who had undergone curative gastrectomy between 1995 and 2011
were enrolled. The Cox proportional hazard regression model was used to evaluate the factors associated with overall
survival (OS). Three-year CS estimates at ‘t’ years after surgery were calculated as follows: CS(t) = S(t + 3)/S(t).
Results: The 1-, 2-, 3-, 4- and 5-year OS rates of the 2935 patients were 96.6 %, 92.0 %, 88.7 %, 85.6 and 82.7 %,
respectively. The probability of surviving an additional 3 years on the condition of having already survived 1, 2, 3,
4 and 5 years after surgery were 88.6 %, 89.9 %, 91.0 %, 92.2 % and 93.2 %, respectively. Patients with a higher risk
at baseline showed a greater increase in CS over time.
Conclusions: CS estimates provide important information about dynamic prognostic changes over time for Korean
gastric cancer patients, and as such, can be used to guide long-term follow-up strategies.
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Background
Despite declining global incidence rates, gastric cancer
remains the fourth most common malignancy and the
second leading cause of worldwide cancer-related mor-
tality [1]. The cornerstone of curative therapy for gastric
cancer remains surgical resection with adequate lymph-
adenectomy. In recent years, there have been many ad-
vances in treatment options, including the establishment
of surgical techniques for tumor resection and lymph
node dissection. Together with progress in adjuvant
chemotherapy, radiotherapy, and molecular-targeted ther-
apy, the long-term outcome of patients with gastric cancer
has improved considerably. Therefore, to maximize the ef-
ficacy of treatment and follow-up strategy, it is important
to establish the prognoses of individual patients and to
apply suitable treatment strategies.
Previous comparisons of risk-grouping approaches in
several diseases using nomograms have shown improved
predictive accuracies. A further potential benefit of no-
mograms is that, through their simple graphical repre-
sentation of a statistical predictive model, they generate
a numerical probability of a clinical event [2].
In general, cancer patient survival is calculated from
the day of operation to the most recent follow-up visit
or death. Traditional survival estimation and initial prog-
nosis assessment at the time of surgery facilitate adju-
vant chemotherapy selection and follow-up scheduling.
This approach, however, lacking postoperative follow-up
information, provides only a static view of risk, because
the prognosis of patients who have already survived for
a certain period of time after their initial treatment is
not the same as the initial prognosis [3, 4]. Furthermore,
patients often ask questions regarding their probability
of survival from the time they begin to visit a clinic for
follow-ups, but physicians and clinicians are unable to
adequately respond based only on the 5-year overall sur-
vival (OS) reported at the time of surgery.
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Conditional survival (CS) estimates are based on the
concept of conditional survival probability [5]. They repre-
sent the probability of surviving additional years condi-
tional to having already survived for a certain period.
Thus they account for changes in hazard rate over time as
well as for dynamic changes in prognosis. The usefulness
of CS estimates has been established for many solid malig-
nancies including urothelial, colorectal, thyroid, ovary,
breast, lung and gastric tumors [3, 4, 6–15]. A multicenter
analysis by the US Gastric Cancer Collaborative indicated
that CS estimates provided important information on
changes in the probability of survival over time [16].
However, to date there has been no comparable study
on Korean patients with gastric cancer. The aims of this
study, therefore, were to estimate, based on the analysis
of a large-scale database, the CS of Korean gastric cancer
patients and to determine its usefulness to those pa-
tients’ prognoses.
Methods
Patients and data collection
In total, 2935 patients who had undergone curative radical
gastrectomy at our hospital between January 1995 and De-
cember 2011 were included in this study. The relevant
demographic, preoperative, postoperative, and pathologic
data were collected from the patients’ medical records.
Preoperative disease assessment was based on physical ex-
aminations, blood tests, chest and abdominal X-rays, en-
doscopy, abdominal computed tomography scans and
positron emission scanning. Pathological staging was
assigned using The American Joint Committee on Cancer
(AJCC; 7th ed.) [17], in which depth of invasion is defined
by T1 tumor invasion of the mucosa and submucosa, T2
tumor invasion of the muscularis propria, T3 tumor pene-
tration of the subserosal connective tissue without inva-
sion of the visceral peritoneum, and T4 tumor invasion of
the serosa (T4a) or adjacent organs (T4b). Data on recur-
rence and overall survival (OS) were collected. Approval
for this study was obtained from the Institutional Review
Board of Seoul St. Mary’s Hospital (KC15RI0252). The re-
search was conducted in compliance with the Helsinki
Declaration.
Only patients undergoing resection with curative in-
tent were enrolled. Patients undergoing palliative resec-
tion and those with known metastatic disease, 30-day
perioperative mortalities, and a history of other organ
malignancies were excluded. For each patient, the fol-
lowing parameters were recorded: age, gender, perform-
ance status according to the Eastern Cooperative
Oncology Group (ECOG) scale, tumor location, resec-
tion extent (total gastrectomy, subtotal gastrectomy
and others), main-tumor size (cm), histologic type (dif-
ferentiated type: well or moderately differentiated tubu-
lar and papillary adenocarcinoma; undifferentiated type:
poorly differentiated adenocarcinoma, signet-ring cell or
mucinous carcinoma), lymphatic invasion (LI), vascular in-
vasion (VI), neural invasion (NI), Lauren classification (in-
testinal, diffuse or mixed type), tumor-node metastasis
(TNM) stage, number of retrieved lymph nodes, and num-
ber of positive nodes.
Conditional survival (CS) estimates
The primary outcome was 3-year CS (CS3) at each time
point. CS is the estimation of the probability that a pa-
tient will survive for an additional number of years given
that he or she has already survived a certain period of
time [17]. The CS3 at ‘t’ years after surgery is defined as
the probability of surviving an additional 3 years after t
years. This was calculated as CS(t)(%) = [S(t + 3)/S(t)] ×
100. The Kaplan-Meier log-rank test and the Cox pro-
portional hazard regression model were used to evaluate
the factors associated with OS. CS was compared with
OS according to the variables determined by multivari-
ate analysis to be independent risk factors for survival.
Statistical analysis
Continuous data were expressed as means ± standard de-
viation. The independent factors significantly related to
patient survival were evaluated with reference to statistics
obtained by the Kaplan-Meier method for calculating OS,
and the multivariate Cox proportional hazard model was
utilized to assess the effects of the variables on OS. All of
the tests were two-sided; statistical significance was prede-
fined at P < 0.05. All of the statistical analyses were per-




The baseline characteristics of the 2935 patients are shown
in Table 1. The mean age was 57.8 years, and 66 % (n =
1424) were male. The majority of patients had a perform-
ance status of 0 or 1. At the time of surgery, the great ma-
jority of patients underwent either a subtotal gastrectomy
(75.4 %) or a total gastrectomy (24.0 %), with the remaining
0.6 % undergoing other operations (either Whipple’s pro-
cedure, proximal gastrectomy or wedge resection). The
mean tumor size was 4.07 cm. With regard to the Lauren
classification, 43.7 % of patients had an intestinal-type
tumor, while the remaining tumors were either diffuse or
of the mixed type. Most tumors were located in the lower
third of the stomach (n = 1632, 55.6 %), and half of the tu-
mors were early-stage cancer (T1 tumors: n = 1594, 54.5
%). Based on the The AJCC (7th ed.) staging system, most
of the patients had stage I tumors (n = 1743, 59.4 %); the
remaining patients had either stage II (n = 553, 18.8 %) or
stage III (n = 639, 21.8 %) tumors (Table 1).
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Prognostic factors associated with overall survival (OS)
Baseline demographic and tumor-characteristic vari-
ables associated with survival were selected for ana-
lysis. A univariate analysis using the Kaplan-Meier
method identified all of the factors, except gender, as
having a significant association with outcome. Accord-
ing to the multivariate analysis, age, performance sta-
tus, tumor size, tumor depth, nodal status, and TNM
stage were each independently associated with OS (all
P < 0.05)(Table 2), which results are consistent with
the findings of relevant previous studies [16, 18].
Table 1 Clinicopathologic characteristics associated with survival
in 2935 patients after curative gastrectomy for gastric cancer
No (%) 5-YSR P* value
Age 0.000
Mean ± SD 57.8 ± 11.95
<60 1511 (51.5) 86.2
≥60 1424 (48.5) 78.8
Sex 0.303
Male 1931 (65.8) 82.0
Female 1004 (34.2) 83.9
ECOG PS 0.000
0 1272 (43.3) 90.6
1 1535 (52.3) 78.2
2 56 (1.9) 53.5
3 4 (1) 50.0
4 1 (0) 0
5 0 (0) -
Unknown 67 (2.3) 85.0
Resection extent 0.000
TG 704 (24.0) 73.3
STG 2212 (75.4) 85.7
Others 19 (0.6) 68.1
Tumor size 0.000
Mean ± SD 4.07 ± 2.80
<5 cm 2004 (68.3) 91.0
≥5 cm 931 (31.7) 65.0
LI 0.000
- 1784 (60.8) 94.5
+ 1130 (38.5) 64.3
Unknown 16 (0.5)
VI 0.000
- 2762 (94.1) 84.1
+ 141 (4.8) 53.5
Unknown 26 (0.9)
NI 0.000
- 2206 (75.2) 89.4
+ 697 (23.7) 62.2
Unknown 25 (0.9)
Leuran classification 0.000
Intestinal 1283 (43.7) 86.1
Diffuse 993 (33.8) 79.9
Mixed 601 (20.5) 69.4
Unknown 58 (2.0)
Histology 0.000
Differentiated 1358 (46.3) 85.5
Undifferentiated 1577 (53.7) 80.1
Table 1 Clinicopathologic characteristics associated with survival
in 2935 patients after curative gastrectomy for gastric cancer
(Continued)
Location 0.000
Esophagus 34 (1.3) 72.3
Upper 1/3 286 (9.7) 80.6
Middle 1/3 947 (32.3) 83.2
Lower 3 1632 (55.6) 82.9
Duodenum 1 (0) 100
Whole Stomach 11 (0.4) 53.3
Unknown 24 (0.8) 100
Depth 0.000
T1 1596 (54.4) 96.0
T2 346 (11.8) 87.4
T3 532 (18.1) 71.6
T4a 442 (15.1) 47.7
T4b 17 (0.5) 48.7
Total number of
Retrieved LN
Mean ± SD 41.62 ± 16.27
Total number of
Positive LN
Mean ± SD 2.56 ± 5.95
Nodal status 0.000
N0 1887 (64.3) 94.3
N1 366 (12.5) 79.8
N2 308 (10.5) 71.2
N3 373 (12.7) 39.3
TNM Stage 0.000
I 1743 (59.4) 96.1
II 553 (18.8) 80.9
III 639 (21.8) 49.7
Continuous variables are presented as the mean ± standard deviation
No, number of patients; 5-YSR, 5-year survival rate; ECOG Eastern cooperative
oncology group, PS Performance status, TG Total gastrectomy, STG Subtotal
gastrectomy, LI Lymphatic invasion, VI Venous invasion, NI Neural invasion, LN
Lymph node, TNM Tumor-node-metastasis
*Log-rank test
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Overall (OS) and conditional survival (CS) estimates
1) Overall patients
Figure 1 shows that the OS decreased over time,
whereas the CS3 increased. The OS at 3 years, 88.7
%, decreased to 80.7 % at 6 years. By contrast, the
CS3 at 3 years, indicating the probability of surviving
an additional 3 years postoperatively, was 91 %.
2) High-risk patients
The calculated CS3 for the strata of the prognostic
factors found on multivariate analysis exceeded the
OS, and the gaps between the OS and CS increased
more prominently in patients with higher risk factors
(i.e., those initially predicted to have a poor outcome)
(Fig. 2). For example, the CS3 at 1- and 4-year OS in
patients with a tumor size of 5 cm or more were 75.7
and 70.6 %, respectively. This difference between CS3
and OS increased, over time, to 36.7 % (CS3 at 7 years:
92.8 %; 10-year OS: 56.1 %) (Fig. 2a). Similarly, the
CS3 at 7 years in patients diagnosed with N2 and N3
were 92.8 and 92.5 %, respectively, whereas the 10-year
OS were 60.7 and 31.0 %, respectively (Fig. 2b). This
trend was prominent also for the T stage (depth of
invasion) and overall stage. For example, the CS3 of
patients with T4b disease increased from 56.3 to 100
%. Finally, the CS3 in patients with stage III disease
increased from 64.7 to 95.1 %, respectively (Fig. 2d).
Interestingly, for patients who were at a more advanced
disease stage, the CS3 was higher at the end of the
study period.
3) Low-risk patients
The CS3 at 1- and 4-year OS in patients with a tumor
size less than 5 cm were 94.5 and 92.7 %, respectively,
and the difference between CS3 and OS after 6
additional years increased only to 11.5 % (CS3 at 7
years: 94.1; 10 year OS: 82.6 %) (Fig. 2a) Furthermore,
the CS3 at 7 years in patients diagnosed with N0 and
N1 were 94.0 and 93.4 %, respectively, whereas the
10-year OS were 85.7 and 72.8 %, respectively (Fig. 2b).
Lastly, the CS3 of patients with T1 disease decreased
slightly from 97.6 to 94.9 % (Fig. 2c), and that of
patients with stage I disease decreased similarly,
from 97.7 to 94.5 % (Fig. 2d).
Discussion
The prognosis of gastric cancer patients usually is eval-
uated in light of the postoperative pathological findings
at the time of initial treatment [18]. In fact, the initial
stage of gastric cancer is defined by the AJCC as one
of its most important prognostic indices, based on
tumor-associated factors such as extent of primary
tumor (T), regional lymph nodes (N), and distant me-
tastases (M) at the time of surgery, thus providing
staged grouping based on T, N and M [17]. Thus far,
many factors have been shown to be of prognostic sig-
nificance to the 5-year survival rate. These include
TNM stage, grade, primary tumor size, tumor location,
lymphatic and vascular invasion, age, and gender [19].
As shown by multivariate analysis, age, performance
status, TNM stage and tumor size are independent
prognostic factors for survival. However, the prognosis
of patients at the same stage is not completely homo-
geneous, and the risk-factor hazard function is not
constant over time. Although prognostic predictions
are useful for guiding the selection of the treatment
modality, they might lose their accuracy once a patient
passes the predicted milestone.
Our present results provide information pertinent to
the conditional 3-year survival rates of patients with
gastric cancer. In this study, as the postoperative time
progressed, the next 3-year survival rates for patients
in each group, stratified by various factors, not only
improved with prolonged survival, but also became similar
Table 2 Independent prognostic factors associated with time to
death at multivariate analysis using cox proportional hazards model

























HR Hazard ratio, CI Confidence interval, ECOG Eastern cooperative oncology
group, PS Performance status, TNM Tumor-node-metastasis
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in value by the end of the study period. The OS rates de-
creased with time, whereas the CS3 estimates increased
with time. Yoshihiro et al. [18] concluded that survival is
not only stage dependent at the time of surgery but also
dependent on the length of survival. They emphasized that
prognoses at 1, 2, 3, 4 and 5 years after the initial operation
differed from those estimated just after surgery, due to the
uncertainty and heterogeneity of the characteristics of this
disease at the time of surgery. Correspondingly, our find-
ings suggest that the probability of patient survival evolves
over time, and that the impacts of initial prognostic factors
decrease with increasing survival [16, 18]. We found that
CS increases markedly over time, especially in patients
with late-stage disease.
The CS estimate, a novel prognostic index, provides
new information relevant to the dynamic prognostic
changes that occur for patients with gastric cancer.
Several studies have shown that CS estimates are
highly significant to the evaluation of the prognostic
prospects of patients with various malignant diseases
[4, 6–16, 20]. Furthermore, it is generally accepted
that patients with poor prognostic features at the time
of initial diagnosis show, compared with those without
these features, greater increases in CS over time. Kim
et al. [16] demonstrated that patients at higher risk at
baseline showed the greatest increases in CS over
time. In their study analyzing 807 patients who had
undergone resection for gastric adenocarcinoma, the
1-, 3- and 5-year OS rates after gastric resection were
42, 34, and 30 %, respectively. The CS estimates,
which is to say, the probabilities of surviving an add-
itional 3 years given that the patient had already sur-
vived 1, 3, and 5 years, were 56, 71, and 82 %,
respectively. Our present 1-, 3- and 5-year OS rates after
initial surgery were much higher than Kim et al.’s: 96.6,
88.7 and 82.7 %, respectively. The discrepancies between
the two cohorts probably are attributable to the fact that
our study population included a relatively high proportion
of patients diagnosed with early-stage disease at pres-
entation. The CS estimates of our patients’ probabil-
ities of surviving an additional 3 years given their
initial 1-, 3- and 5-year survivals were 88.6, 91.0 and
93.2 %, respectively. The subsequent 3-year survival
rates of patients with worse prognostic factors ap-
peared to approximate, as time passed, those of pa-
tients without such risk factors, and the patients with
poorer prognostic factors (i.e., tumor size ≥ 5 cm, T4b,
N3, stage III) showed the greatest increases in CS over
time. This is due to the fact that the death hazard in
patients with gastric cancer is highest during the first
few years after the initial surgery, and those who are
expected to die based on the estimated 5-year OS typ-
ically experience disease recurrence and death during
that period [8].
There is a critical limitation to this study. Although
we enrolled relatively large numbers of patients, selec-
tion bias might have been occurred in diagnosis, treat-
ment, and the follow-up schedule, due simply to the
study’s retrospective nature. Also, comorbidity data, ad-
juvant chemotherapy treatment, socioeconomic status
and educational level were not evaluated as factors in
predicting survival.
In recent years, patients with gastric cancer have
been able to survive longer than those diagnosed a few
decades ago [1]. This is thanks partly to higher rates
of early detection, the development of better chemo-
therapeutic agents, and improved postoperative care.
More than 50 % of patients undergoing gastrectomy in
Korea are diagnosed with early gastric cancer. This
positive trend, however, has necessitated more accur-
ate prognostic assessment for correspondingly en-
hanced treatment planning and follow-up strategies
[8, 21]. Since many Korean gastric cancer patients
have a good chance for long-term survival, CS esti-
mation is even more important than for Western pa-
tient populations.
Fig. 1 Survival analysis. a Overall survival (OS) curve of 2935 enrolled patients, b 3-year conditional survival (CS) relative to actuarial survival. The
number in parentheses represents the exact OS time-point after surgery
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Conclusions
In conclusion, we demonstrated that CS improves over
time following resection for gastric cancer. The adoption
of CS estimates can help surgeons and oncologists to bet-
ter predict survival, make the most appropriate treatment
decisions, and conduct a more fully informed discussion
with patients in light of their survival expectancy or prog-
nosis. This is very important, particularly as many patients
are followed closely for years after surgery, and natur-
ally, they desire to know how long they can expect to
survive. For further work, the risk-factor hazard func-
tion, the impact of which on survival varies over time,
should be evaluated. Moreover, detailed knowledge of
time-dependent risk profiles is required for improved
prediction of survival and better-individualized follow-
up strategies.
Fig. 2 Comparison of OS with CS, stratified by a tumor size, b nodal status, c tumor depth, and d AJCC stage. The number in parentheses represents
the exact OS time-point after surgery
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